Fotemustine
Primary CNS Lymphoma (PCNSL)
Mingzhi ZhangSmall moleculePhase 4 / ApprovedDormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Primary CNS Lymphoma (PCNSL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Teniposide Huashan Hospital | Phase 4 | BB |
Epcoritamab The Lymphoma Academic Research Organisation | Phase 2 | B |
Anbalcabtagene Autoleucel Hyungwoo Cho | Phase 2 | CCC |
nb02 NOBO Medicine | Phase 2 | CCC |
Benadryl Hyungwoo Cho | Phase 2 | CCC |
Same molecule, other indications
Fotemustine is also rated in:
Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms NeoplasmsDormant
B
Indicative ·
60 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →